Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.
Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.
Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness,...
Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.
The U.S. Supreme Court on Monday declined to hear a pharmaceutical industry challenge to the Medicare drug price negotiation program created under the Inflation Reduction Act, leaving in place lower court...